Trajectories of Blood Pressure in Patients with Established Coronary Artery Disease over 20 Years

Overview

Journal Int J Hypertens

Publisher Wiley

Date 2022 Oct 13

PMID 36225816

Authors

Piotr Jankowski

Pawel Koziel

Grzegorz Bilo

Jaroslaw Pinkas

Danuta Czarnecka

Kalina Kawecka-Jaszcz

Andrzej Pajak

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate changes in blood pressure (BP) values in patients with established coronary artery disease (CAD) over 20 years (1997-2017).

Materials And Methods: Consecutive patients aged <71 years and hospitalized for acute coronary syndrome or myocardial revascularization procedures were recruited and interviewed 6-18 months after their discharge from the hospital. BP was measured in 1997-1998, 1999-2000, 2006-2007, 2011-2013, and 2016-2017. The same five hospitals took part in the surveys at each time point.

Results: We examined 412 patients in 1997-1998, 427 in 1999-2000, 422 in 2006-2007, 462 in 2011-2013, and 272 in 2016-2017. The proportion of patients with BP at the recommended goal was 49.2% in 1997-98, 44.5% in 1999-2000, 44.7% in 2006-07, 51.1% in 2011-13, and 58.8% in 2016-17 ( < 0.001). Mean systolic and diastolic BP decreased significantly independent of age, sex, and education (systolic BP: 137.9 ± 21.4 mmHg in 1997-98, 139.5 ± 21.6 mmHg in 1999-2000, 136.1 ± 20.3 mmHg in 2006-07, 134.8 ± 22.0 mmHg in 2011-13, and 134.2 ± 18.6 mmHg in 2016-17, < 0.001; diastolic BP: 83.4 ± 11.0 mmHg in 1997-98, 84.8 ± 12.0 mmHg in 1999-2000, 85.2 ± 11.0 mmHg in 2006-07, 80.9 ± 12.5 mmHg in 2011-13, and 81.1 ± 10.4 mmHg in 2016-17; < 0.001).

Conclusion: The analysis of five multicenter surveys provides evidence of a decrease in BP in patients with established CAD over two decades. This trend is independent of age, sex, and the education level of the patients.

References

Denolle T, Pellen C, Serandour A, Lebreton S, Revault dAllonnes F . Persistence of uncontrolled hypertension post-cardiac rehabilitation in stable coronary patients. J Hum Hypertens. 2021; 36(6):537-543. DOI: 10.1038/s41371-021-00544-1. View

Jankowski P, Banach M, Malyszko J, Mastej M, Tykarski A, Narkiewicz K . May Measurement Month 2018: an analysis of blood pressure screening campaign results from Poland. Eur Heart J Suppl. 2020; 22(Suppl H):H108-H111. PMC: 7455275. DOI: 10.1093/eurheartj/suaa041. View

Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D . Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019; 26(8):824-835. DOI: 10.1177/2047487318825350. View

Jankowski P, Kawecka-Jaszcz K, Pajak A, Bilo G, Dubiel J, Maciejewicz J . [Cracovian program for secondary prevention of ischemic heart disease. Secondary prevention of ischemic heart disease after discharge in 1997-98 and 1999-2000]. Przegl Lek. 2003; 60(3):142-6. View

Pajak A, Jankowski P, Kawecka-Jaszcz K, Surowiec S, Wolfshaut R, Loster M . Changes in secondary prevention of coronary artery disease in the post-discharge period over the decade 1997-2007. Results of the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease and Polish parts of the EUROASPIRE II and III.... Kardiol Pol. 2010; 67(12):1353-9. View

Jankowski P, Kosior D, Sowa P, Szostak-Janiak K, Koziel P, Krzykwa A . Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey. Cardiol J. 2020; 27(5):533-540. PMC: 8078981. DOI: 10.5603/CJ.a2020.0072. View

Jankowski P, Kawecka-Jaszcz K, Bilo G, Pajak A . Determinants of poor hypertension management in patients with ischaemic heart disease. Blood Press. 2005; 14(5):284-92. DOI: 10.1080/08037050500239962. View

. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998; 19(10):1434-503. DOI: 10.1053/euhj.1998.1243. View

Hejjaji V, Gosch K, Jones P, Breeding T, Spertus J, Arnold S . Comanagement of Risk Factors in Patients With Coronary Artery Disease: Insights From the APPEAR Study. J Am Heart Assoc. 2020; 9(11):e015157. PMC: 7428978. DOI: 10.1161/JAHA.119.015157. View

10.

Pallares-Carratala V, Bonig-Trigueros I, Palazon-Bru A, Esteban-Giner M, Gil-Guillen V, Giner-Galvan V . Clinical inertia in hypertension: a new holistic and practical concept within the cardiovascular and clinical care process. Blood Press. 2019; 28(4):217-228. DOI: 10.1080/08037051.2019.1608134. View

11.

Jankowski P, Czarnecka D, Lysek R, Skrzek A, Smas-Suska M, Mazurek A . Secondary prevention in patients after hospitalisation due to coronary artery disease: what has changed since 2006?. Kardiol Pol. 2014; 72(4):355-62. DOI: 10.5603/KP.a2013.0350. View

12.

Niklas A, Flotynska A, Puch-Walczak A, Polakowska M, Topor-Madry R, Polak M . Prevalence, awareness, treatment and control of hypertension in the adult Polish population - Multi-center National Population Health Examination Surveys - WOBASZ studies. Arch Med Sci. 2018; 14(5):951-961. PMC: 6111367. DOI: 10.5114/aoms.2017.72423. View

13.

Ostchega Y, Hughes J, Zhang G, Nwankwo T, Graber J, Nguyen D . Differences in Hypertension Prevalence and Hypertension Control by Urbanization Among Adults in the United States, 2013-2018. Am J Hypertens. 2021; 35(1):31-41. PMC: 8897826. DOI: 10.1093/ajh/hpab067. View

14.

Pedersen E, Garcia B, Halvorsen K, Eggen A, Schirmer H, Waaseth M . Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Tromsø 7. BMC Cardiovasc Disord. 2021; 21(1):44. PMC: 7819182. DOI: 10.1186/s12872-021-01866-1. View

15.

White W, Jalil F, Cushman W, Bakris G, Bergenstal R, Heller S . Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. J Am Heart Assoc. 2018; 7(20):e009114. PMC: 6474950. DOI: 10.1161/JAHA.118.009114. View

16.

Mancia G, Fagard R . New blood pressure control goals, more rational but facilitating therapeutic inertia? : reply. J Hypertens. 2013; 31(12):2463. DOI: 10.1097/HJH.0000000000000005. View

17.

Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by.... Eur Heart J. 2016; 37(29):2315-2381. PMC: 4986030. DOI: 10.1093/eurheartj/ehw106. View

18.

Kotseva K, De Bacquer D, Jennings C, Gyberg V, De Backer G, Ryden L . Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013. Glob Heart. 2016; 12(4):315-322.e3. DOI: 10.1016/j.gheart.2015.11.003. View

19.

Koziel P, Jankowski P, Mirek-Bryniarska E, Nessler J, Podolec P, De Bacquer D . Obesity in patients with established coronary artery disease over a 20-year period (1997-2017). Pol Arch Intern Med. 2021; 131(1):26-32. DOI: 10.20452/pamw.15742. View

20.

Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R . European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.... Eur Heart J. 2007; 28(19):2375-414. DOI: 10.1093/eurheartj/ehm316. View